Advanced search
Publication Cover
mAbs Volume 15, 2023 - Issue 1
Submit an article Journal homepage
14,609
Views
20
CrossRef citations to date
0
Altmetric
Review

Assessing developability early in the discovery process for novel biologics

Monica L. Fernández-Quinteroa Center for Molecular Biosciences Innsbruck (CMBI), Department of General, Inorganic and Theoretical Chemistry, University of Innsbruck, Innsbruck, AustriaORCID Iconhttps://orcid.org/0000-0002-6811-6283View further author information
ORCID Icon,
Anne Ljungarsb Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, DenmarkORCID Iconhttps://orcid.org/0000-0002-2158-0601View further author information
ORCID Icon,
Franz Waibla Center for Molecular Biosciences Innsbruck (CMBI), Department of General, Inorganic and Theoretical Chemistry, University of Innsbruck, Innsbruck, AustriaORCID Iconhttps://orcid.org/0000-0003-0527-0803View further author information
ORCID Icon,
Victor Greiffc Department of Immunology, University of Oslo, Oslo, NorwayORCID Iconhttps://orcid.org/0000-0003-2622-5032View further author information
ORCID Icon,
Jan Terje Andersend Department of Immunology, University of Oslo, Oslo University Hospital Rikshospitalet, Oslo, Norway;e Institute of Clinical Medicine and Department of Pharmacology, University of Oslo, Oslo, NorwayORCID Iconhttps://orcid.org/0000-0003-1710-1628View further author information
ORCID Icon,
Torleif T. Gjølbergf Authera AS, Oslo Science Park, Oslo, NorwayORCID Iconhttps://orcid.org/0000-0002-1719-7677View further author information
ORCID Icon,
Timothy P. Jenkinsb Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, DenmarkORCID Iconhttps://orcid.org/0000-0003-2979-5663View further author information
ORCID Icon,
Bjørn Gunnar Voldborgg National Biologics Facility, Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, DenmarkORCID Iconhttps://orcid.org/0000-0002-7005-1642View further author information
ORCID Icon,
Lise Marie Gravb Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, DenmarkORCID Iconhttps://orcid.org/0000-0001-8042-7108View further author information
ORCID Icon,
Sandeep Kumarh Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USAORCID Iconhttps://orcid.org/0000-0003-2840-6398View further author information
ORCID Icon,
Guy Georgesi Roche Pharma Research and Early Development, Large Molecule Research, Roche Innovation Center Munich, Penzberg, GermanyORCID Iconhttps://orcid.org/0000-0001-5737-006XView further author information
ORCID Icon,
Hubert Kettenbergeri Roche Pharma Research and Early Development, Large Molecule Research, Roche Innovation Center Munich, Penzberg, GermanyORCID Iconhttps://orcid.org/0000-0001-7130-1917View further author information
ORCID Icon,
Klaus R. Liedla Center for Molecular Biosciences Innsbruck (CMBI), Department of General, Inorganic and Theoretical Chemistry, University of Innsbruck, Innsbruck, AustriaORCID Iconhttps://orcid.org/0000-0002-0985-2299View further author information
ORCID Icon,
Peter M. Tessierj Department of Chemical Engineering, Pharmaceutical Sciences and Biomedical Engineering, Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan, USAORCID Iconhttps://orcid.org/0000-0002-3220-007XView further author information
ORCID Icon,
John McCaffertyk Department of Medicine, Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK;l Maxion Therapeutics, Babraham Research Campus, Cambridge, UKORCID Iconhttps://orcid.org/0000-0003-2195-0972View further author information
ORCID Icon &
Andreas H. Laustsenb Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, DenmarkCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6918-5574View further author information
ORCID Icon show all
Article: 2171248 | Received 27 Oct 2022, Accepted 18 Jan 2023, Published online: 23 Feb 2023

References

  • Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9(3):203–19.
  • Bailly M, Mieczkowski C, Juan V, Metwally E, Tomazela D, Baker J, Uchida M, Kofman E, Raoufi F, Motlagh S, et al. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening. MAbs. 2020;12(1):1743053.
  • Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, et al. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci U S A. 2017;114(5):944–49.
  • Gutierrez L, Cauchon NS, Christian TR, Giffin MJ, Abernathy MJ. The Confluence of Innovation in Therapeutics and Regulation: Recent CMC Considerations. J Pharm Sci. 2020;109(12):3524–34.
  • Jarasch A, Koll H, Regula JT, Bader M, Papadimitriou A, Kettenberger H. Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci. 2015;104(6):1885–98.
  • Strohl WR, Strohl LM. 1-Introduction to biologics and monoclonal antibodies. Therapeutic Antibody Engineering. Woodhead Publishing Series in Biomedicine. Sawston, Cambridge: Woodhead Publishing; 2012. p. 1–595.
  • Pucca MB, Cerni FA, Janke R, Bermúdez-Méndez E, Ledsgaard L, Barbosa JE, Laustsen AH. History of Envenoming Therapy and Current Perspectives. Front Immunol. 2019;10:1598.
  • Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–97.
  • Walsh G. Biopharmaceutical benchmarks 2018. Nat Biotechnol. 2018;36(12):1136–45.
  • Ros F, Offner S, Klostermann S, Thorey I, Niersbach H, Breuer S, Zarnt G, Lorenz S, Puels J, Siewe B, et al. Rabbits transgenic for human IgG genes recapitulating rabbit B-cell biology to generate human antibodies of high specificity and affinity. MAbs. 2020;12(1):1846900.
  • Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol. 2005;23(9):1117–25.
  • Lee E-C, Liang Q, Ali H, Bayliss L, Beasley A, Bloomfield-Gerdes T, Bonoli L, Brown R, Campbell J, Carpenter A, et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat Biotechnol. 2014;32(4):356–63.
  • Drabek D, Janssens R, van Haperen R, Grosveld F, Transgenic Heavy A. Chain IgG Mouse Platform as a Source of High Affinity Fully Human Single-Domain Antibodies for Therapeutic Applications. In: Hussack G, Henry KA, editors. Single-Domain Antibodies: Methods and Protocols. New York, NY: Springer US; 2022. p. 121–41.
  • Lee E-C OM. The Application of Transgenic Mice for Therapeutic Antibody Discovery. In: Proetzel G, Ebersbach H, editors. Antibody Methods and Protocols. Totowa, NJ: Humana Press; 2012. p. 137–48.
  • Gray AC, Bradbury A, Dübel S, Knappik A, Plückthun A, Borrebaeck CAK. Reproducibility: bypass animals for antibody production. Nature. 2020; 581:262.
  • Bradbury ARM, Dübel S, Knappik A, Plückthun A. Animal- versus in vitro -derived antibodies: avoiding the extremes. MAbs. 2021;13(1):1950265.
  • Gray A, Bradbury ARM, Knappik A, Plückthun A, Borrebaeck CAK, Dübel S. Animal-free alternatives and the antibody iceberg. Nat Biotechnol. 2020;38(11):1234–39.
  • Borrebaeck CAK, Ohlin M. Antibody evolution beyond Nature. Nat Biotechnol. 2002;20(12):1189–90.
  • Ledsgaard L, Ljungars A, Rimbault C, Sørensen CV, Tulika T, Wade J, Wouters Y, McCafferty J, Laustsen AH. Advances in antibody phage display technology. Drug Discov Today. 2022;27(8):2151–69.
  • Starr CG, Tessier PM. Selecting and engineering monoclonal antibodies with drug-like specificity. Curr Opin Biotechnol. 2019;60:119–27.
  • Laustsen AH, Greiff V, Karatt-Vellatt A, Muyldermans S, Jenkins TP. Animal Immunization in Vitro Display Technologies, and Machine Learning for Antibody Discovery. Trends Biotechnol. 2021;39(12):1263–73.
  • Dobson CL, Devine PWA, Phillips JJ, Higazi DR, Lloyd C, Popovic B, Arnold J, Buchanan A, Lewis A, Goodman J, et al. Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo. Sci Rep. 2016;6(1):38644.
  • Dyson MR, Masters E, Pazeraitis D, Perera RL, Syrjanen JL, Surade S, Thorsteinson N, Parthiban K, Jones PC, Sattar M, et al. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries. MAbs. 2020;12(1):1829335.
  • Buchanan A, Clementel V, Woods R, Harn N, Bowen MA, Mo W, Popovic B, Bishop SM, Dall’Acqua W, Minter R, et al. Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression. MAbs. 2013;5(2):255–62.
  • Bethea D, Wu S-J, Luo J, Hyun L, Lacy ER, Teplyakov A, Jacobs SA, O’Neil KT, Gilliland GL, Feng Y. Mechanisms of self-association of a human monoclonal antibody CNTO607. Protein Eng Des Sel. 2012;25(10):531–37.
  • McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990;348(6301):552–54.
  • Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D, Christ D. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci U S A. 2012;109(27):10879–84.
  • Famm K, Hansen L, Christ D, Winter G. Thermodynamically stable aggregation-resistant antibody domains through directed evolution. J Mol Biol. 2008;376(4):926–31.
  • Boublik Y, Di Bonito P, Jones IM. Eukaryotic virus display: engineering the major surface glycoprotein of the Autographa californica nuclear polyhedrosis virus (AcNPV) for the presentation of foreign proteins on the virus surface. Biotechnology. 1995;13(10):1079–84.
  • Plückthun A. Ribosome display: a perspective. Methods Mol Biol. 2012;805:3–28.
  • Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. 1997;15(6):553–57.
  • Parthiban K, Perera RL, Sattar M, Huang Y, Mayle S, Masters E, Griffiths D, Surade S, Leah R, Dyson MR, et al. A comprehensive search of functional sequence space using large mammalian display libraries created by gene editing. MAbs. 2019;11(5):884–98.
  • Avery LB, Wade J, Wang M, Tam A, King A, Piche-Nicholas N, Kavosi MS, Penn S, Cirelli D, Kurz JC, et al. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. MAbs. 2018;10(2):244–55.
  • Cunningham O, Scott M, Zhou ZS, Finlay WJJ. Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns. MAbs. 2021;13(1):1999195.
  • Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301(5638):1374–77.
  • Rabia LA, Zhang Y, Ludwig SD, Julian MC, Tessier PM, Daggett V. Net charge of antibody complementarity-determining regions is a key predictor of specificity. Protein Eng Des Sel. 2018;31(11):409–18.
  • Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artyomov MN, Pietzsch J, Connors M, Pereyra F, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 2010;467(7315):591–95.
  • Makowski EK, Wu L, Desai AA, Tessier PM. Highly sensitive detection of antibody nonspecific interactions using flow cytometry. MAbs. 2021;13(1):1951426.
  • Hötzel I, Theil F-P, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs. 2012;4(6):753–60.
  • Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu T-Y, Torrey J, Thomas J, Bobrowicz P, Vásquez M, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel. 2013;26(10):663–70.
  • Tessier PM, Sandler SI, Lenhoff AM. Direct measurement of protein osmotic second virial cross coefficients by cross-interaction chromatography. Protein Sci. 2004;13(5):1379–90.
  • A-M WP, Sormanni P, Andersen JS, Sakhnini LI, Rodriguez-Leon I, Bjelke JR, Gajhede AJ, De Maria L, Otzen DE, Vendruscolo M, et al. In vitro and in silico assessment of the developability of a designed monoclonal antibody library. MAbs. 2019;11(2):388–400.
  • Jacobs SA, Wu S-J, Feng Y, Bethea D, O’Neil KT. Cross-interaction chromatography: a rapid method to identify highly soluble monoclonal antibody candidates. Pharm Res. 2010;27(1):65–71.
  • Kelly RL, Sun T, Jain T, Caffry I, Yu Y, Cao Y, Lynaugh H, Brown M, Vásquez M, Wittrup KD, et al. High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs. 2015;7(4):770–77.
  • Kohli N, Jain N, Geddie ML, Razlog M, Xu L, Lugovskoy AA. A novel screening method to assess developability of antibody-like molecules. MAbs. 2015;7(4):752–58.
  • Kraft TE, Richter WF, Emrich T, Knaupp A, Schuster M, Wolfert A, Kettenberger H. Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis. MAbs. 2020;12(1):1683432.
  • Haverick M, Mengisen S, Shameem M, Ambrogelly A. Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications. MAbs. 2014;6(4):852–58.
  • Roettger BF, Ladisch MR. Hydrophobic interaction chromatography. Biotechnol Adv. 1989;7(1):15–29.
  • Tessier PM, Wu J, Dickinson CD. Emerging methods for identifying monoclonal antibodies with low propensity to self-associate during the early discovery process. Expert Opin Drug Deliv. 2014;11(4):461–65.
  • Starr CG, Makowski EK, Wu L, Berg B, Kingsbury JS, Gokarn YR, Tessier PM. Ultradilute Measurements of Self-Association for the Identification of Antibodies with Favorable High-Concentration Solution Properties. Mol Pharm. 2021;18(7):2744–53.
  • Shahfar H, Du Q, Parupudi A, Shan L, Esfandiary R, Roberts CJ. Electrostatically Driven Protein-Protein Interactions: Quantitative Prediction of Second Osmotic Virial Coefficients to Aid Antibody Design. J Phys Chem Lett. 2022;13(5):1366–72.
  • Tessier PM, Lenhoff AM, Sandler SI. Rapid measurement of protein osmotic second virial coefficients by self-interaction chromatography. Biophys J. 2002;82(3):1620–31.
  • Patro SY, Przybycien TM. Self-interaction chromatography: a tool for the study of protein-protein interactions in bioprocessing environments. Biotechnol Bioeng. 1996;52(2):193–203.
  • Wu J, Schultz JS, Weldon CL, Sule SV, Chai Q, Geng SB, Dickinson CD, Tessier PM. Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy. Protein Eng Des Sel. 2015;28(10):403–14.
  • Estep P, Caffry I, Yu Y, Sun T, Cao Y, Lynaugh H, Jain T, Vásquez M, Tessier PM, Xu Y. An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies. MAbs. 2015;7(3):553–61.
  • Liu Y, Caffry I, Wu J, Geng SB, Jain T, Sun T, Reid F, Cao Y, Estep P, Yu Y, et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. MAbs. 2014;6:483–92.
  • Sule SV, Sukumar M, Weiss WF. 4th, Marcelino-Cruz AM, Sample T, Tessier PM. High-throughput analysis of concentration-dependent antibody self-association. Biophys J. 2011;101:1749–57.
  • Hu S, Datta-Mannan A, D’Argenio DZ. Physiologically Based Modeling to Predict Monoclonal Antibody Pharmacokinetics in Humans from in vitro Physiochemical Properties. MAbs. 2022;14(1):2056944.
  • Phan S, Walmer A, Shaw EW, Chai Q. High-throughput profiling of antibody self-association in multiple formulation conditions by PEG stabilized self-interaction nanoparticle spectroscopy. MAbs. 2022;14(1):2094750.
  • Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, et al. Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs. 2019;11(2):239–64.
  • Kopp MRG, A-M WP, Zucca MV, Capasso Palmiero U, Friedrichsen B, Lorenzen N, Arosio P. An accelerated surface-mediated stress assay of antibody instability for developability studies. MAbs. 2020;12(1):1815995.
  • Wilman W, Wróbel S, Bielska W, Deszynski P, Dudzic P, Jaszczyszyn I, Kaniewski J, Młokosiewicz J, Rouyan A, Satława T, et al. Machine-designed biotherapeutics: opportunities, feasibility and advantages of deep learning in computational antibody discovery. Brief Bioinform 2022;23.
  • Khetan R, Curtis R, Deane CM, Hadsund JT, Kar U, Krawczyk K, Kuroda D, Robinson SA, Sormanni P, Tsumoto K, et al. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics. MAbs. 2022;14(1):2020082.
  • Akbar R, Bashour H, Rawat P, Robert PA, Smorodina E, Cotet T-S, Flem-Karlsen K, Frank R, Mehta BB, Vu MH, et al. Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies. MAbs. 2022;14(1):2008790.
  • Norman RA, Ambrosetti F, Bonvin AMJJ, Colwell LJ, Kelm S, Kumar S, Krawczyk K. Computational approaches to therapeutic antibody design: established methods and emerging trends. Brief Bioinform. 2020;21(5):1549–67.
  • Wang B, Gallolu Kankanamalage S, Dong J, Liu Y. Optimization of therapeutic antibodies. Antib Ther. 2021;4(1):45–54.
  • Gaa R, Menang-Ndi E, Pratapa S, Nguyen C, Kumar S, Doerner A. Versatile and rapid microfluidics-assisted antibody discovery. MAbs. 2021;13(1):1978130.
  • Narayanan H, Dingfelder F, Butté A, Lorenzen N, Sokolov M, Arosio P. Machine Learning for Biologics: Opportunities for Protein Engineering, Developability, and Formulation. Trends Pharmacol Sci. 2021;42(3):151–65.
  • Bachas S, Rakocevic G, Spencer D, Sastry AV, Haile R, Sutton JM, Kasun G, Stachyra A, Gutierrez JM, Yassine E, et al. Antibody optimization enabled by artificial intelligence predictions of binding affinity and naturalness. bioRxiv. 2022;1–39.
  • Kumar S, Singh SK. Developability of Biotherapeutics: Computational Approaches. Boca Raton: CRC Press; 2015.
  • Kumar S, Plotnikov NV, Rouse JC, Singh SK. Biopharmaceutical Informatics: supporting biologic drug development via molecular modelling and informatics. J Pharm Pharmacol. 2018;70(5):595–608.
  • Ruffolo JA, Sulam J, Gray JJ. Antibody structure prediction using interpretable deep learning. Patterns (N Y). 2022;3(2):100406.
  • Leem J, Dunbar J, Georges G, Shi J, Deane CM. ABodyBuilder: Automated antibody structure prediction with data-driven accuracy estimation. MAbs. 2016;8(7):1259–68.
  • Ruffolo JA, Chu L-S, Mahajan SP, Gray JJ. Fast, accurate antibody structure prediction from deep learning on massive set of natural antibodies. bioRxiv. 2022 Aug15. doi:10.1101/2022.04.20.488972.
  • Marks C, Deane CM. How repertoire data are changing antibody science. J Biol Chem. 2020;295(29):9823–37.
  • Almagro JC, Beavers MP, Hernandez-Guzman F, Maier J, Shaulsky J, Butenhof K, Labute P, Thorsteinson N, Kelly K, Teplyakov A, et al. Antibody modeling assessment. Proteins. 2011;79(11):3050–66.
  • Abanades B, Georges G, Bujotzek A, Deane CM, Xu J. ABlooper: Fast accurate antibody CDR loop structure prediction with accuracy estimation. Bioinformatics. 2022;38(7): 1877–80.
  • Ruffolo JA, Guerra C, Mahajan SP, Sulam J, Gray JJ. Geometric potentials from deep learning improve prediction of CDR H3 loop structures. Bioinformatics. 2020;36(Supplement_1):i268–75.
  • Ahmed L, Gupta P, Martin KP, Scheer JM, Nixon AE, Kumar S. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics. Proc Natl Acad Sci U S A.2021; 118(37): e2020577118.
  • Raybould MIJ, Marks C, Krawczyk K, Taddese B, Nowak J, Lewis AP, Bujotzek A, Shi J, Deane CM. Five computational developability guidelines for therapeutic antibody profiling. Proc Natl Acad Sci U S A. 2019;116(10):4025–30.
  • Boswell CA, Tesar DB, Mukhyala K, Theil F-P, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010;21(12):2153–63.
  • Dall’Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol. 2002;169(9):5171–80.
  • Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I, et al. In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proc Natl Acad Sci U S A. 2014;111(52):18601–06.
  • Chung S, Nguyen V, Lin YL, Lafrance-Vanasse J, Scales SJ, Lin K, Deng R, Williams K, Sperinde G, Li JJ, et al. An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans. MAbs. 2019;11:942–55.
  • Conti S, Lau EY, Ovchinnikov V. On the Rapid Calculation of Binding Affinities for Antigen and Antibody Design and Affinity Maturation Simulations. Antibodies. 2022;11(3):51.
  • Ahmad B, Batool M, Kim M-S CS, Choi S. Computational-Driven Epitope Verification and Affinity Maturation of TLR4-Targeting Antibodies. Int J Mol Sci. 2021; 22. (11): 5989.
  • Goulet DR, Chatterjee S, Lee W-P, Waight AB, Zhu Y, Mak AN-S. Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability. Antibodies (Basel). 2022;11(1): 11.
  • Marks C, Hummer AM, Chin M, Deane CM. Humanization of antibodies using a machine learning approach on large-scale repertoire data. Bioinformatics. 2021;37(22): 4041–47.
  • Prihoda D, Maamary J, Waight A, Juan V, Fayadat-Dilman L, Svozil D, Bitton DA. BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning. MAbs. 2022;14(1):2020203.
  • Wade J, Rimbault C, Ali H, Ledsgaard L, Rivera-de-Torre E, Abou Hachem M, Boddum K, Mirza N, Bohn M-F, Sakya SA, et al. Generation of Multivalent Nanobody-Based Proteins with Improved Neutralization of Long α-Neurotoxins from Elapid Snakes. Bioconjug Chem. 2022;33(8):1494–504.
  • Kumar S, Roffi K, Tomar DS, Cirelli D, Luksha N, Meyer D, Mitchell J, Allen MJ, Li L. Rational optimization of a monoclonal antibody for simultaneous improvements in its solution properties and biological activity. Protein Eng Des Sel. 2018;31(7–8):313–25.
  • Nichols P, Li L, Kumar S, Buck PM, Singh SK, Goswami S, Balthazor B, Conley TR, Sek D, Allen MJ. Rational design of viscosity reducing mutants of a monoclonal antibody: Hydrophobic versus electrostatic inter-molecular interactions. MAbs. 2015;7(1):212–30.
  • Bauer J, Mathias S, Kube S, Otte K, Garidel P, Gamer M, Blech M, Fischer S, Karow-Zwick AR. Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain. MAbs. 2020;12(1):1787121.
  • Prabakaran R, Rawat P, Yasuo N, Sekijima M, Kumar S, Gromiha MM. Effect of charged mutation on aggregation of a pentapeptide: Insights from molecular dynamics simulations. Proteins. 2022;90(2):405–17.
  • Prabakaran R, Rawat P, Kumar S, Michael Gromiha M. ANuPP: A Versatile Tool to Predict Aggregation Nucleating Regions in Peptides and Proteins. J Mol Biol. 2021;433(11):166707.
  • Tomar DS, Li L, Broulidakis MP, Luksha NG, Burns CT, Singh SK, Kumar S. In-silico prediction of concentration-dependent viscosity curves for monoclonal antibody solutions. MAbs. 2017;9(3):476–89.
  • Tomar DS, Kumar S, Singh SK, Goswami S, Li L. Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development. MAbs. 2016;8(2):216–28.
  • Tomar DS, Singh SK, Li L, Broulidakis MP, Kumar S. In Silico Prediction of Diffusion Interaction Parameter (kD), a Key Indicator of Antibody Solution Behaviors. Pharm Res. 2018;35(10):193.
  • Agrawal NJ, Helk B, Kumar S, Mody N, Sathish HA, Samra HS, Buck PM, Li L, Trout BL. Computational tool for the early screening of monoclonal antibodies for their viscosities. MAbs. 2016;8(1):43–48.
  • Buck PM, Chaudhri A, Kumar S, Singh SK. Highly viscous antibody solutions are a consequence of network formation caused by domain-domain electrostatic complementarities: insights from coarse-grained simulations. Mol Pharm. 2015;12(1):127–39.
  • Hashemi A, Basafa M, Behravan A. Machine learning modeling for solubility prediction of recombinant antibody fragment in four different E. coli strains Sci Rep. 2022;12(1):5463.
  • Khurana S, Rawi R, Kunji K, Chuang G-Y, Bensmail H, Mall R, Valencia A. DeepSol: a deep learning framework for sequence-based protein solubility prediction. Bioinformatics. 2018;34(15):2605–13.
  • Lai P-K, Fernando A, Cloutier TK, Kingsbury JS, Gokarn Y, Halloran KT, Calero-Rubio C, Trout BL. Machine Learning Feature Selection for Predicting High Concentration Therapeutic Antibody Aggregation. J Pharm Sci. 2021;110(4):1583–91.
  • Rawat P, Prabakaran R, Kumar S, Gromiha MM. Exploring the sequence features determining amyloidosis in human antibody light chains. Sci Rep. 2021;11(1):13785.
  • Plotnikov NV, Singh SK, Rouse JC, Kumar S. Quantifying the Risks of Asparagine Deamidation and Aspartate Isomerization in Biopharmaceuticals by Computing Reaction Free-Energy Surfaces. J Phys Chem B. 2017;121(4):719–30.
  • Kaliman I, Nemukhin A, Varfolomeev S. Free Energy Barriers for the N-Terminal Asparagine to Succinimide Conversion: Quantum Molecular Dynamics Simulations for the Fully Solvated Model. J Chem Theory Comput. 2010;6(1):184–89.
  • Salsbury Jr FR Jr. Molecular dynamics simulations of protein dynamics and their relevance to drug discovery. Curr Opin Pharmacol. 2010;10(6):738–44.
  • Hashemi N, Hao B, Ignatov M, Paschalidis I, Vakili P, Vajda S, Kozakov D. Improved Predictions of MHC-Peptide Binding using Protein Language Models. bioRxiv. 2022. doi:10.1101/2022.02.11.479844.
  • Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48(W1):W449–54.
  • Tomar DS, Licari G, Bauer J, Singh SK, Li L, Kumar KS. Stress-dependent Flexibility of a Full-length Human Monoclonal Antibody: Insights from Molecular Dynamics to Support Biopharmaceutical Development. J Pharm Sci. 2022;111(3):628–37.
  • Chen X, Dougherty T, Hong C, Schibler R, Zhao YC, Sadeghi R, Matasci N, Wu Y-C KI. Predicting Antibody Developability from Sequence using Machine Learning. bioRxiv. 2020. doi:10.1101/2020.06.18.159798
  • Lai P-K, Fernando A, Cloutier TK, Gokarn Y, Zhang J, Schwenger W, Chari R, Calero-Rubio C, Trout BL. Machine Learning Applied to Determine the Molecular Descriptors Responsible for the Viscosity Behavior of Concentrated Therapeutic Antibodies. Mol Pharm. 2021;18(3):1167–75.
  • Amimeur T, Shaver JM, Ketchem RR, Alex Taylor J, Clark RH, Smith J, Van Citters D, Siska CC, Smidt P, Sprague M, et al. Designing Feature-Controlled Humanoid Antibody Discovery Libraries Using Generative Adversarial Networks. bioRxiv. 2020. doi:10.1101/2020.04.12.024844
  • Akbar R, Robert PA, Weber CR, Widrich M, Frank R, Pavlović M, Scheffer L, Chernigovskaya M, Snapkov I, Slabodkin A, et al. In silico proof of principle of machine learning-based antibody design at unconstrained scale. MAbs. 2022;14(1):2031482.
  • Khan A, Cowen-Rivers AI, Deik D-G-X, Grosnit A, Dreczkowski K, Robert PA, Greiff V, Tutunov R, Bou-Ammar D, Wang J, et al. AntBO: Towards Real-World Automated Antibody Design with Combinatorial Bayesian Optimisation. Cell Reports Methods. 2023;3: 100374.
  • Makowski EK, Kinnunen PC, Huang J, Wu L, Smith MD, Wang T, Desai AA, Streu CN, Zhang Y, Zupancic JM, et al. Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space. Nat Commun. 2022;13(1):3788.
  • Freschlin CR, Fahlberg SA, Romero PA. Machine learning to navigate fitness landscapes for protein engineering. Curr Opin Biotechnol. 2022;75:102713.
  • Das P, Sercu T, Wadhawan K, Padhi I, Gehrmann S, Cipcigan F, Chenthamarakshan V, Strobelt H, Dos Santos C, Chen P-Y, et al. Accelerated antimicrobial discovery via deep generative models and molecular dynamics simulations. Nat Biomed Eng. 2021;5(6):613–23.
  • Robert PA, Akbar R, Frank R, Pavlović M, Widrich M, Snapkov I, Chernigovskaya M, Scheffer L, Slabodkin A, Mehta BB , et al. One billion synthetic 3D-antibody-antigen complexes enable unconstrained machine-learning formalized investigation of antibody specificity prediction Nature Computational Science. 2022;2:845-865.
  • Sandve GK, Greiff V. Access to ground truth at unconstrained size makes simulated data as indispensable as experimental data for bioinformatics methods development and benchmarking. Bioinformatics. 2022.
  • Weber CR, Akbar R, Yermanos A, Pavlović M, Snapkov I, Sandve GK, Reddy ST, Greiff V, Schwartz R. immuneSIM: tunable multi-feature simulation of B- and T-cell receptor repertoires for immunoinformatics benchmarking. Bioinformatics. 2020;36(11):3594–96.
  • Jafari M, Guan Y, Wedge DC, Ansari-Pour N. Re-evaluating experimental validation in the Big Data Era: a conceptual argument. Genome Biol. 2021;22(1):71.
  • Kralj S, Hodošček M, Podobnik B, Kunej T, Bren U, Janežič D, Konc J. Molecular Dynamics Simulations Reveal Interactions of an IgG1 Antibody With Selected Fc Receptors. Front Chem. 2021;9:705931.
  • Ieong P, Amaro RE, Li WW. Molecular dynamics analysis of antibody recognition and escape by human H1N1 influenza hemagglutinin. Biophys J. 2015;108(11):2704–12.
  • Fernández-Quintero ML, Pomarici ND, Math BA, Kroell KB, Waibl F, Bujotzek A, Georges G, Liedl KR. Antibodies exhibit multiple paratope states influencing VH-VL domain orientations. Commun Biol. 2020;3(1):589.
  • Henzler-Wildman K, Kern D. Dynamic personalities of proteins. Nature. 2007;450(7172):964–72.
  • Fernández-Quintero ML, Georges G, Varga JM, Liedl KR. Ensembles in solution as a new paradigm for antibody structure prediction and design. MAbs. 2021;13(1):1923122.
  • Schrag JD, M-è P, Gaudreault F, Gagnon L-P, Baardsnes J, Manenda MS, Sheff J, Deprez C, Baptista C, Hogues H, et al. Binding symmetry and surface flexibility mediate antibody self-association. MAbs. 2019;11(7):1300–18.
  • Samantray S, Schumann W, Illig A-M, Carballo-Pacheco M, Paul A, Barz B, Strodel B. Molecular Dynamics Simulations of Protein Aggregation: Protocols for Simulation Setup and Analysis with Markov State Models and Transition Networks. In: Li MS, Kloczkowski A, Cieplak M, Kouza M, editors. Computer Simulations of Aggregation of Proteins and Peptides. New York, NY: Springer US; 2022. p. 235–79.
  • Schmid I, Bonnington L, Gerl M, Bomans K, Thaller AL, Wagner K, Schlothauer T, Falkenstein R, Zimmermann B, Kopitz J, et al. Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions. Commun Biol. 2018;1(1):28.
  • Bekker G-J, Ma B, Kamiya N. Thermal stability of single-domain antibodies estimated by molecular dynamics simulations. Protein Sci. 2019;28(2):429–38.
  • Fernández-Quintero ML, Kraml J, Georges G, Liedl KR. CDR-H3 loop ensemble in solution - conformational selection upon antibody binding. MAbs. 2019;11(6):1077–88.
  • Fernández-Quintero ML, Kroell KB, Heiss MC, Loeffler JR, Quoika PK, Waibl F, Bujotzek A, Moessner E, Georges G, Liedl KR. Surprisingly Fast Interface and Elbow Angle Dynamics of Antigen-Binding Fragments. Front Mol Biosci. 2020;7:609088.
  • Fernández-Quintero ML, Hoerschinger VJ, Lamp LM, Bujotzek A, Georges G, Liedl KR. V H -V L interdomain dynamics observed by computer simulations and NMR. Proteins. 2020;88(7):830–39.
  • Regep C, Georges G, Shi J, Popovic B, Deane CM. The H3 loop of antibodies shows unique structural characteristics. Proteins. 2017;85(7):1311–18.
  • Waibl F, Fernández-Quintero ML, Kamenik AS, Kraml J, Hofer F, Kettenberger H, Georges G, Liedl KR. Conformational Ensembles of Antibodies Determine Their Hydrophobicity. Biophys J. 2021;120(1):143–57.
  • Waibl F, ML F-Q, FS W, Kettenberger H, Georges G, KR L. Comparison of hydrophobicity scales for predicting biophysical properties of antibodies. Frontiers in Molecular Biosciences. 2022;9:960194.
  • Fernández-Quintero ML, Kokot J, Waibl F, Fischer A-LM, Quoika PK, Deane CM, Liedl KR. Challenges in antibody structure prediction. bioRxiv. 2022. doi:10.1101/2022.11.09.515600.
  • Fernández-Quintero ML, Heiss MC, Pomarici ND, Math BA, Liedl KR. Antibody CDR loops as ensembles in solution vs. canonical clusters from X-ray structures. MAbs. 2020;12:1744328.
  • Fernández-Quintero ML, Vangone A, Loeffler JR, Seidler CA, Georges G, Liedl KR. Paratope states in solution improve structure prediction and docking. Structure. 2022;30(3):430–40.e3.
  • Hauptmann A, Hoelzl G, Loerting T. Distribution of Protein Content and Number of Aggregates in Monoclonal Antibody Formulation After Large-Scale Freezing. AAPS PharmSciTech. 2019;20(2):72.
  • Chakroun N, Hilton D, Ahmad SS, Platt GW, Dalby PA. Mapping the Aggregation Kinetics of a Therapeutic Antibody Fragment. Mol Pharm. 2016;13(2):307–19.
  • Robinson MJ, Matejtschuk P, Bristow AF, Dalby PA. T m -Values and Unfolded Fraction Can Predict Aggregation Rates for Granulocyte Colony Stimulating Factor Variant Formulations but Not under Predominantly Native Conditions. Mol Pharm. 2018;15(1):256–67.
  • Jo S, Xu A, Curtis JE, Somani S. MacKerell AD Jr. Computational Characterization of Antibody-Excipient Interactions for Rational Excipient Selection Using the Site Identification by Ligand Competitive Saturation-Biologics Approach. Mol Pharm. 2020;17:4323–33.
  • Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci. 2012;101(1):102–15.
  • Sankar K, Krystek SR, Carl SM, Day T, Maier JKX. AggScore: Prediction of aggregation-prone regions in proteins based on the distribution of surface patches. Proteins. 2018;86(11):1147–56.
  • Olsson MHM, Søndergaard CR, Rostkowski M, Jensen JH. PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. J Chem Theory Comput. 2011;7(2):525–37.
  • Swails JM, York DM, Roitberg AE. Constant pH Replica Exchange Molecular Dynamics in Explicit Solvent Using Discrete Protonation States: Implementation, Testing, and Validation. J Chem Theory Comput. 2014;10(3):1341–52.
  • Radak BK, Chipot C, Suh D, Jo S, Jiang W, Phillips JC, Schulten K, Constant-pH Molecular RB. Dynamics Simulations for Large Biomolecular Systems. J Chem Theory Comput. 2017;13(12):5933–44.
  • Thacker SG, Her C, Kelley-Baker L, Ireland DDC, Manangeeswaran M, Pang ES, Verthelyi D. Detection of innate immune response modulating impurities (IIRMI) in therapeutic peptides and proteins: Impact of excipients. Front Immunol. 2022;13:970499.
  • Modernizing medical product development through collaboration. FDA Consum 2006; 40:5.
  • Vaisman-Mentesh A, Rosenstein S, Yavzori M, Dror Y, Fudim E, Ungar B, Kopylov U, Picard O, Kigel A, Ben-Horin S, et al. Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists. Front Immunol. 2019;10:2921.
  • Garcês S, Demengeot J. The Immunogenicity of Biologic Therapies. Curr Probl Dermatol. 2018;53:37–48.
  • Krishna M, Nadler SG. Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes. Front Immunol. 2016;7:21.
  • Pratt KP. Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity. Antibodies (Basel). 2018;7(2):1-18.
  • Horton C, Shanmugarajah K, Fairchild PJ. Harnessing the properties of dendritic cells in the pursuit of immunological tolerance. Biomed J. 2017;40(2):80–93.
  • Blumberg RS,Lillicrap D, IgG Fc Immune Tolerance Group. Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia. Blood. 2018;131(20):2205-2214.
  • Jawa V, Terry F, Gokemeijer J, Mitra-Kaushik S, Roberts BJ, Tourdot S, De Groot AS. T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020. Front Immunol. 2020;11:1301.
  • De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, Scott DW, Martin W. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes.”. Blood. 2008;112(8):3303–11.
  • Lutfi RA. Informational processing of complex sound I: Intensity discrimination. J Acoust Soc Am. 1989;86:934–44.
  • Committee for Medicinal Products for Human Use (CHMP). Guideline on Immunogenicity assessment of therapeutic proteins. European Medicines Agency; 2017.
  • U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products. 2014.
  • Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–25.
  • Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS. The Neonatal Fc Receptor (FcRn): A Misnomer?. Front Immunol. 2019;10:1540.
  • Grevys A, Nilsen J, Sand KMK, Daba MB, Øynebråten I, Bern M, McAdam MB, Foss S, Schlothauer T, Michaelsen TE. A human endothelial cell-based recycling assay for screening of FcRn targeted molecules. Nat Commun. 2018;9(1):621.
  • Schlothauer T, Rueger P, Stracke JO, Hertenberger H, Fingas F, Kling L, Emrich T, Drabner G, Seeber S, Auer J, et al. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. MAbs. 2013;5(4):576–86.
  • Nilsen J, Trabjerg E, Grevys A, Azevedo C, Brennan SO, Stensland M, Wilson J, Sand KMK, Bern M, Dalhus B, et al. An intact C-terminal end of albumin is required for its long half-life in humans. Commun Biol. 2020;3(1):181.
  • Gjølberg TT, Frick R, Mester S, Foss S, Grevys A, Høydahl LS, Øk J, Schlothauer T, Sandlie I, Moe MC, et al. Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life. Commun Biol. 2022;5(1):832.
  • Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci USA. 2015;112(19):5997–6002.
  • Acquiring PM. English at different ages: the English displacement effect and other findings. J Psycholinguist Res. 1990;19(1):57–70.
  • Gan Z, Ram S, Ober RJ, Ward ES. Using multifocal plane microscopy to reveal novel trafficking processes in the recycling pathway. J Cell Sci. 2013;126(5):1176–88.
  • Louis FJ, Fargier JJ, Maubert B, Louis JP, Hounsinou C, Le Bras J, Touzé JE. Severe malaria attacks in adults in Cameroon: comparison of 2 therapeutic protocols using quinine via parenteral route. Ann Soc Belg Med Trop. 1992;72:179–88.
  • Foss S, Grevys A, Sand KMK, Bern M, Blundell P, Michaelsen TE, Pleass RJ, Sandlie I, Andersen JT. Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization. J Control Release. 2016;223:42–52.
  • Deissler HL, Lang GK, Lang GE. Neonatal Fc receptor FcRn is involved in intracellular transport of the Fc fusion protein aflibercept and its transition through retinal endothelial cells. Exp Eye Res. 2017;154:39–46.
  • Hubbard JJ, Pyzik M, Rath T, Kozicky LK, Sand KMK, Gandhi AK, Grevys A, Foss S, Menzies SC, Glickman JN, et al. FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity. J Exp Med 2020;217(10).
  • Shimotsu H, Kuroda MI, Yanofsky C, Henner DJ. Novel form of transcription attenuation regulates expression the Bacillus subtilis tryptophan operon. J Bacteriol. 1986;166(2):461–71.
  • Longo JM, Rodríguez-Cabello J, Bilbao JI, Aquerreta JD, Ruza M, Mansilla F. Popliteal vein thrombosis and popliteal artery compression complicating fibular osteochondroma: ultrasound diagnosis. J Clin Ultrasound. 1990;18(6):507–09.
  • Baker K, Rath T, Lencer WI, Fiebiger E, Blumberg RS. Cross-presentation of IgG-containing immune complexes. Cell Mol Life Sci. 2013;70:1319–34.
  • Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature. 1994;372(6504):379–83.
  • Raghavan M, Wang Y, Bjorkman PJ. Effects of receptor dimerization on the interaction between the class I major histocompatibility complex-related Fc receptor and IgG. Proc Natl Acad Sci U S A. 1995;92(24):11200–04.
  • Berschneider HM, Martens H, Powell DW. Effect of BW 942C, an enkephalinlike pentapeptide, on sodium and chloride transport in the rabbit ileum. Gastroenterology. 1988;94(1):127–36.
  • Shehata L, Maurer DP, Wec AZ, Lilov A, Champney E, Sun T, Archambault K, Burnina I, Lynaugh H, Zhi X, et al. Affinity Maturation Enhances Antibody Specificity but Compromises Conformational Stability. Cell Rep. 2019;28(13):3300–3308.
  • Grevys A, Frick R, Mester S, Flem-Karlsen K, Nilsen J, Foss S, Sand KMK, Emrich T, Fischer JAA, Greiff V, et al. Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life. iScience. 2022;25(2):103746.
  • Schmidt EGW, Hvam ML, Antunes F, Cameron J, Viuff D, Andersen B, Kristensen NN, Howard KA. Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin. J Biol Chem. 2017;292(32):13312–22.
  • Sockolosky JT, Tiffany MR, Szoka FC. Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proc Natl Acad Sci U S A. 2012;109(40):16095–100.
  • Liu C, Kim YS, Lowe JH-N, Chung S. A cell-based FcRn-dependent recycling assay for predictive pharmacokinetic assessment of therapeutic antibodies. Bioanalysis. 2021;13(14):1135–44.
  • Claypool SM, Dickinson BL, Yoshida M, Lencer WI, Blumberg RS. Functional reconstitution of human FcRn in Madin-Darby canine kidney cells requires co-expressed human beta 2-microglobulin. J Biol Chem. 2002;277(31):28038–50.
  • Ramalingam TS, Detmer SA, Martin WL, Bjorkman PJ. IgG transcytosis and recycling by FcRn expressed in MDCK cells reveals ligand-induced redistribution. EMBO J. 2002;21(4):590–601.
  • Weflen AW, Baier N, Tang Q-J, Van den Hof M, Blumberg RS, Lencer WI, Massol RH, Gruenberg JE. Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules. Mol Biol Cell. 2013;24(15):2398–405.
  • Gan Z, Ram S, Vaccaro C, Ober RJ, Ward ES. Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. Traffic. 2009;10(5):600–14.
  • Sato K, Howell JN, Greene MH, Maher VM, McCormick JJ. Relationship between sensitivity of cells from patients with hereditary cutaneous malignant melanoma to killing and mutations by 4-nitroquinoline 1-oxide and adduct formation. Cancer Res. 1988;48:5145–50.
  • Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, Yeilding N, Davis HM, Zhou H. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49(2):162–75.
  • Lima XT, Abuabara K, Kimball AB, Lima HC. Briakinumab. Expert Opin Biol Ther. 2009;9(8):1107–13.
  • Jensen PF, Schoch A, Larraillet V, Hilger M, Schlothauer T, Emrich T, Rand KD. A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life. Mol Cell Proteomics. 2017;16(3):451–56.
  • Piche-Nicholas NM, Avery LB, King AC, Kavosi M, Wang M, O’Hara DM, Tchistiakova L, Katragadda M. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics. MAbs. 2018;10(1):81–94.
  • Bern M, Nilsen J, Ferrarese M, Sand KMK, Gjølberg TT, Lode HE, Davidson RJ, Camire RM, Bækkevold ES, Foss S, et al. An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. Sci Transl Med. 2020;12(565):1-13.
  • Liang W-C, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber H-P, Ferrara N, et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem. 2006;281(2):951–61.
  • Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci. 2008;49(2):522–27.
  • Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 2001;13(12):1551–59.
  • Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem. 2010;285(7):4826–36.
  • Low BE, Christianson GJ, Lowell E, Qin W, Wiles MV. Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human FCGRT transgenic mice. MAbs. 2020;12(1):1829334.
  • Lee C-H, Kang TH, Godon O, Watanabe M, Delidakis G, Gillis CM, Sterlin D, Hardy D, Cogné M, Macdonald LE, et al. An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence. Nat Commun. 2019;10(1):5031.
  • Mariani G, Abbeele AD, Venkateshan CN, Kaldany A, Ito S, Adelstein SJ, Kassis AI. Monoclonal antibody internalization by tumor cells: an experimental model for potential radioimmunotherapy applications. Int J Rad Appl Instrum B. 1989;16(2):147–50.
  • Roopenian DC, Low BE, Christianson GJ, Proetzel G, Sproule TJ, Wiles MV. Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs. MAbs. 2015;7(2):344–51.
  • Avery LB, Wang M, Kavosi MS, Joyce A, Kurz JC, Fan -Y-Y, Dowty ME, Zhang M, Zhang Y, Cheng A, et al. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs. 2016;8(6):1064–78.
  • Tam SH, McCarthy SG, Brosnan K, Goldberg KM, Scallon BJ. Correlations between pharmacokinetics of IgG antibodies in primates vs FcRn-transgenic mice reveal a rodent model with predictive capabilities . MAbs. 2013;5:397–405.
  • Huggins MA, Jameson SC, Hamilton SE. Embracing microbial exposure in mouse research. J Leukoc Biol. 2019;105(1):73–79.
  • Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol. 2006;18(12):1759–69.
  • Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, Petkova S, Avanessian L, Choi EY, Shaffer DJ, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol. 2003;170:3528–33.
  • Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest. 1970;49(4):673–80.
  • Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun. 2011;2(1):599.
  • Nilsen J, Bern M, Sand KMK, Grevys A, Dalhus B, Sandlie I, Andersen JT. Human and mouse albumin bind their respective neonatal Fc receptors differently. Sci Rep. 2018;8(1):14648.
  • Andersen JT, Dalhus B, Viuff D, Ravn BT, Gunnarsen KS, Plumridge A, Bunting K, Antunes F, Williamson R, Athwal S. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. J Biol Chem. 2014;289(19):13492–502. .
  • Viuff D, Antunes F, Evans L, Cameron J, Dyrnesli H, Thue Ravn B, Stougaard M, Thiam K, Andersen B, Kjærulff S, et al. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs. J Control Release. 2016;223:22–30.
  • Mandrup OA, Ong SC, Lykkemark S, Dinesen A, Rudnik-Jansen I, Dagnæs-Hansen NF, Andersen JT, Alvarez-Vallina L, Howard KA. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity. Commun Biol. 2021;4(1):310.
  • Silverman AD, Karim AS, Jewett MC. Cell-free gene expression: an expanded repertoire of applications. Nat Rev Genet. 2020;21(3):151–70.
  • Tihanyi B, Nyitray L. Recent advances in CHO cell line development for recombinant protein production. Drug Discov Today Technol. 2020;38:25–34.
  • Yang W, Zhang J, Xiao Y, Li W, Wang T. Screening Strategies for High-Yield Chinese Hamster Ovary Cell Clones. Front Bioeng Biotechnol. 2022;10:858478.
  • Sergeeva D, Lee GM, Nielsen LK, Grav LM. Multicopy Targeted Integration for Accelerated Development of High-Producing Chinese Hamster Ovary Cells. ACS Synth Biol. 2020;9(9):2546–61.
  • Lee JS, Kildegaard HF, Lewis NE, Lee GM. Mitigating Clonal Variation in Recombinant Mammalian Cell Lines. Trends Biotechnol. 2019;37(9):931–42.
  • Rajendran S, Balasubramanian S, Webster L, Lee M, Vavilala D, Kulikov N, Choi J, Tang C, Hunter M, Wang R, et al. Accelerating and de-risking CMC development with transposon-derived manufacturing cell lines. Biotechnol Bioeng. 2021;118(6):2301–11.
  • Kol S, Ley D, Wulff T, Decker M, Arnsdorf J, Schoffelen S, Hansen AH, Jensen TL, Gutierrez JM, Chiang AWT, et al. Multiplex secretome engineering enhances recombinant protein production and purity. Nat Commun. 2020;11(1):1908.
  • Amann T, Hansen AH, Kol S, Hansen HG, Arnsdorf J, Nallapareddy S, Voldborg B, Lee GM, Andersen MR, Kildegaard HF. Glyco-engineered CHO cell lines producing alpha-1-antitrypsin and C1 esterase inhibitor with fully humanized N-glycosylation profiles. Metab Eng. 2019;52:143–52.
  • Dovgan T, Golghalyani V, Zurlo F, Hatton D, Lindo V, Turner R, Harris C, Targeted CT. CHO cell engineering approaches can reduce HCP-related enzymatic degradation and improve mAb product quality. Biotechnol Bioeng. 2021;118(10):3821–31.
  • Ha TK, Hansen AH, Kildegaard HF, Lee GM. Knockout of sialidase and pro-apoptotic genes in Chinese hamster ovary cells enables the production of recombinant human erythropoietin in fed-batch cultures. Metab Eng. 2020;57:182–92.
  • Heffner KM, Wang Q, Hizal DB, Ö C, Betenbaugh MJ. Glycoengineering of Mammalian Expression Systems on a Cellular Level. Adv Biochem Eng Biotechnol. 2021;175:37–69.
  • Sifniotis V, Cruz E, Eroglu B, Kayser V. Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and Formulation. Antibodies (Basel). 2019;8(2): 1–39.
  • van der Kant R, Karow-Zwick AR, Van Durme J, Blech M, Gallardo R, Seeliger D, Aßfalg K, Baatsen P, Compernolle G, Gils A, et al. Prediction and Reduction of the Aggregation of Monoclonal Antibodies. J Mol Biol. 2017;429:1244–61.
  • Crawford Y, Zhou M, Hu Z, Joly J, Snedecor B, Shen A, Gao A. Fast identification of reliable hosts for targeted cell line development from a limited-genome screening using combined φC31 integrase and CRE-Lox technologies. Biotechnol Prog. 2013;29(5):1307–15.
  • Scarcelli JJ, Shang TQ, Iskra T, Allen MJ, Zhang L. Strategic deployment of CHO expression platforms to deliver Pfizer’s Monoclonal Antibody Portfolio. Biotechnol Prog. 2017;33(6):1463–67.
  • Shen Y, Burakov D, Chen G, Fandl JP. CHO integration sites and uses thereof. US Patent2017. https://patentimages.storage.googleapis.com/da/c7/31/8fda4baae3bd0d/US9816110.pdf
  • Chen K, Zhu Y, Zhang Y, Hamza T, Yu H, Saint Fleur A, Galen J, Yang Z, Feng H. A probiotic yeast-based immunotherapy against Clostridioides difficile infection. Sci Transl Med. 2020;12(567):1-11.
  • Zhao H, Tasch M, Dodds M, Gewe M, Martinez A, Hutton M, Keeney K, Pollock A, Jester B, Khuong N, et al. Using antibody synergy to engineer a high potency biologic cocktail against C. difficile. bioRxiv. 2022; doi:10.1101/2021.12.21.473715.
  • Sarker SA, Jäkel M, Sultana S, Alam NH, Bardhan PK, Chisti MJ, Salam MA, Theis W, Hammarström L, Frenken LGJ. Anti-rotavirus protein reduces stool output in infants with diarrhea: a randomized placebo-controlled trial. Gastroenterology. 2013;145(4):740–8.e8.
  • Fiil BK, Thrane SW, Pichler M, Kittilä T, Ledsgaard L, Ahmadi S, Hermansen GMM, Jelsbak L, Lauridsen C, Brix S, et al. Orally active bivalent VHH construct prevents proliferation of F4+ enterotoxigenic Escherichia coli in weaned piglets. iScience. 2022;25(4):104003.
  • Butler JE, Wertz N, Deschacht N, Porcine Igg: KI. structure, genetics, and evolution. Immunogenetics. 2009;61(3):209–30.
  • Virdi V, Palaci J, Laukens B, Ryckaert S, Cox E, Vanderbeke E, Depicker A, Callewaert N. Yeast-secreted, dried and food-admixed monomeric IgA prevents gastrointestinal infection in a piglet model. Nat Biotechnol. 2019;37(5):527–30.
  • Pellis M, Pardon E, Zolghadr K, Rothbauer U, Vincke C, Kinne J, Dierynck I, Hertogs K, Leonhardt H, Messens J, et al. A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional Nanobodies. Arch Biochem Biophys. 2012;526(2):114–23.
  • Kunz P, Ortale A, Mücke N, Zinner K, Hoheisel JD. Nanobody stability engineering by employing the ΔTm shift; a comparison with apparent rate constants of heat-induced aggregation. Protein Eng Des Sel. 2019;32(5):241–49.
  • Hagihara Y, Mine S, Uegaki K. Stabilization of an immunoglobulin fold domain by an engineered disulfide bond at the buried hydrophobic region. J Biol Chem. 2007;282(50):36489–95.
  • Saerens D, Conrath K, Govaert J, Muyldermans S. Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains. J Mol Biol. 2008;377(2):478–88.
  • Hussack G, Hirama T, Ding W, Mackenzie R, Tanha J. Engineered single-domain antibodies with high protease resistance and thermal stability. PLoS One. 2011;6(11):e28218.
  • Jester BW, Zhao H, Gewe M, Adame T, Perruzza L, Bolick DT, Agosti J, Khuong N, Kuestner R, Gamble C, et al. Development of spirulina for the manufacture and oral delivery of protein therapeutics. Nat Biotechnol. 2022;40(6):956–64.
  • Saberianfar R, Chin-Fatt A, Scott A, Henry KA, Topp E, Plant-Produced Chimeric MR. VHH-sIgA Against Enterohemorrhagic E. coli Intimin Shows Cross-Serotype Inhibition of Bacterial Adhesion to Epithelial Cells . Front Plant Sci. 2019;10:270.
  • Shanmugaraj B, I Bulaon CJ, Phoolcharoen W. Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production. Plants. 2020;9(7):842.
  • De Meyer T, Laukens B, Nolf J, Van Lerberge E, De Rycke R, De Beuckelaer A, De Buck S, Callewaert N, Depicker A. Comparison of VHH-Fc antibody production in Arabidopsis thaliana, Nicotiana benthamiana and Pichia pastoris. Plant Biotechnol J. 2015;13(7):938–47.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.